Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies High-dose therapy and autologous stem cell transplantation (ASCT) remains an integral component of myeloma therapy. 1 The traditional approach in patients considered eligible for ASCT consists of initial therapy with 4 --6 cycles of a non-alkylatorcontaining regimen, followed by ASCT. Until the advent of novel agents like thalidomide, lenalidomide or bortezomib, VAD (vincristine, adriamycin, dexamethasone) or single-agent dexamethasone were the used induction regimens, neither of which had any impact on peripheral blood stem cell (PBSC) mobilization. The combination of lenalidomide and dexamethasone (Len --Dex) results in high-response rates in newly diagnosed myeloma 2 and has become a commonly used initial therapy. Previous studies suggested that lenalidomide therapy could result in suboptimal PBSC collection. 3 --6 The results vary significantly across different studies; likely reflective of treatment duration, age, mobilization regimens and collection targets. 7 --9 We retrospectively examined the results of the PBSC collection in a large cohort of patients receiving initial therapy with Len --Dex to clearly define the problem, the risk factors and alternative approaches to mobilization. The study included 224 patients undergoing PBSC collection between July 2004 and December 2009, following Len --Dex induction. PBSC were collected using granulocyte colony-stimulating factor (G-CSF) or G-CSF plus cyclophosphamide (CTX), or G-CSF plus plerixafor as previously described. 3 Among these, 48 patients were included in the previous report demonstrating the impact of lenalidomide on mobilization.
3 G-CSF was administered subcutaneously (10 mg/kg) daily, followed by a peripheral blood CD34 (PB-CD34) count on day 4 (days counted from first day of G-CSF). If the PB-CD34 count is X10/ml, patients initiate collection the next day (day 5); otherwise, it is rechecked and apheresis initiated once they reach the threshold. Patients failing to reach the PB-CD34 threshold by day 5 typically had G-CSF increased to 16 mg/kg twice daily. CTX 1.5 g/m 2 was given on 2 consecutive days in those with high-residual tumor burden, followed by G-CSF until collection was completed. Plerixafor was used either as part of upfront mobilization trials or as per the risk adapted algorithm we developed (February 2009 --November 2009). For patients with PB-CD34 o10/ml on day 4, it was measured again on day 5; if it was still o10/ml, plerixafor (0.24 mg/kg subcutaneously) was administered on day 5 evening and apheresis was commenced the following day. In addition, if daily collection yield was o0.5 Â 10 6 CD34 per kg, plerixafor was added. G-CSF and plerixafor continued daily until apheresis was complete. The collection target was 2 (minimum) to 4 (ideal) million CD34 cells per kg per planned transplant. The study was conducted with the approval of the Institutional Review Board. Several parameters were used to compare efficacy of PBSC collection: total CD34 yield, number of collections, number of collection days, average CD34 collection per day, total CD34 yield on day 1, percentage of target CD34 collected, percentage of patients who failed to collect X2 million and/or X4 million CD 34 cells per kg.
The median age at mobilization of the entire cohort was 60.6 years (range 29 --76); of these, 136 (60%) were male. A total of 245 collection attempts were made among 224 patients, 21 (9.8%) patients attempting to remobilize after failing to reach the PBSC target initially. The median duration of lenalidomide therapy before PBSC collection was 4 months (range 1 --26).
We first analyzed the results of the first mobilization in the 224 patients. The mobilization strategies were G-CSF alone in 151 (67%) patients, chemo mobilization with CTX followed by G-CSF in 29 (13%) patients, and G-CSF plus plerixafor in 44 (20%) patients (Table 1) . Among those receiving plerixafor, it was used upfront in a planned fashion in 10 patients and as a risk-adapted approach in 34 patients. Overall 15 patients (7%) failed to reach the PB-CD34 counts required to initiate apheresis, and among those starting apheresis 6 patients failed to collect X2 million CD34 cells per kg; a cumulative failure rate of 9%. Another 18 (8%) patients failed to collect X4 million CD34 cells per kg. The CD34 yield on day 1, day 1 plus 2, the total yield, number of collections, average daily yield and percentage of the targeted cells collected for each mobilization strategy are detailed in Table 1 . Only 29 patients (13%) received CTX; they had significantly higher day-1 CD34 count, total CD34 counts, average daily CD34 collection, and percent of target CD34 collected, with fewer collection days and lower failure rates. The day-1 CD 34 collection including the average daily and total CD34 collections were significantly lower with G-CSF alone compared with either G-CSF þ CTX or plerixafor ( Figure 1a ). All 10 patients (4%) receiving plerixafor upfront collected X4 million per kg CD34 cells. Among the 34 (15%) patients in whom plerixafor was added on the basis of the risk-adapted algorithm; only 6% and 15% of patients failed to achieve the minimum (2 million per kg) and ideal (4 million per kg) collection goal, respectively.
We then examined the risk factors for poor mobilization (o4 million CD34 cells per kg), specifically looking at the age, duration of lenalidomide and the time between discontinuation of lenalidomide and mobilization, restricting the analysis to the G-CSF only cohort. In univariate analysis, only the age significantly influenced poor mobilization, and the best cutoff for age predicting for a poor mobilization was over 66 years. Among those over 66 years of age, 31% failed to collect X4 million CD34 cells compared with 10% of the rest (Po0.01). The collection was also slower among the older group (Figure 1b ). There was no significant relationship between duration of lenalidomide or the time between last dose of lenalidomide and start of collection and the risk of mobilization failure.
Twenty-one patients re-attempted mobilization, including 14 who failed first attempt and 7 who collected X2 million CD34 cells per kg, but did not achieve the intended goal. The mobilization regimens were G-CSF alone, CTX þ GCSF, GCSF þ GM-CSF (granulocyte macrophage CSF) and G-CSF þ plerixafor in 5, 8, 3 and 4 patients, respectively. All patients collected X2 million CD34 cells per kg and 14 patients (70%) collected X4 million CD34 cells per kg. The median collection was 5.4 million per kg (range 2 --19.5), bringing the median total collection for these 21 patients to 9.6 million per kg (range 2.6 --19.6). Excluding the 6 patients who failed to mobilize with the first attempt and did not re-attempt a mobilization, all the remaining 218 patients collected X2 million CD34 cells per kg and 197 (90%) collected X4 million CD34 cells per kg.
In the current analysis, we systematically studied a large cohort of consecutive patients with myeloma, initially treated with lenalidomide. First, our study confirms the previous observations of a failure (o2 million CD34 cells per kg) rate of around 9% among this patient group. 3, 4 Overall, nearly 10% of patients underwent remobilization after failing to reach the target at the first attempt. As shown previously, age at mobilization was a significant predictor for success of mobilization. As has been shown before, the stem cell yield was significantly higher in patients treated with CTX þ G-CSF than with G-CSF alone. 8 Although the use of chemotherapy allows the better stem cell collection, it lengthens the collection process, delays the platelet engraftment and is associated with increased risk of infectious complications. 10 Overall, the results are consistent with a recent report from Cavallo et al., 7 in a group of uniformly treated patients Letters to the Editor who received CTX and G-CSF mobilization following four cycles of lenalidomide. Given the wider spectrum of duration of induction therapy and the types of mobilization regimens used, the current study complements the results of the previous study. One of the recent advances has been the introduction of plerixafor, a CXCR4 inhibitor. Interaction between the chemokine stromal cell-derived factor 1 and the CXCR4 receptor is an important mechanism for stem cell retention in the marrow.
11 As demonstrated in the previous reports, 12,13 patients who received plerixafor upfront in a planned fashion had higher CD34 numbers and fewer apheresis days compared with G-CSF alone or G-CSF þ CTX. Importantly, the risk adapted use of plerixafor successfully rescued patients who failed to reach the peripheral CD34 threshold. We have previously shown that the probability of a collection X2 million CD34 per kg among patients failing to reach the threshold by day 5 was only 50%.
14
In conclusion, the current study represents one of the largest groups of patients described so far in the context of mobilization following a lenalidomide-containing regimen and provides two important messages. Although the overall failure rate of stem cell collection in patients receiving initial therapy with lenalidomide is around 10%, use of chemo mobilization or a risk-adapted approach of adding plerixafor appears to decrease the risk of failure. However, the initial collection failure results in increase resource utilization in terms of growth factor use, re-attempts using chemotherapy or plerixafor, hospitalizations, need for transfusions and antibiotics for neutropenic fever. The approach of using plerixafor selectively in patients with a high likelihood of failure as shown by the risk-adapted strategy used here is likely to be associated with less cost than routine upfront use on all patients.
14,15 More importantly, the majority of patients failing a stem-cell harvest attempt can be salvaged with a second collection, allowing these patients to proceed to a stem cell transplant if so desired. We have recently generated a conditional loss-of-function allele of the Traf3 gene that allows specific deletion of TRAF3 in B lymphocytes in mice (B-TRAF3 À/À mice). 5 These mice exhibit greatly expanded B-cell populations in secondary lymphoid organs, due to remarkably prolonged, BAFF-independent survival of mature B cells, a finding subsequently confirmed by Gardam et al.
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6 TRAF3 and TRAF2 assemble to form a regulatory complex with cIAP1/2 and NIK to inhibit the NF-kB2-signaling pathway. 7, 8 These observations define a central role of the TRAF3--NIK--NF-kB2 axis in regulating B-cell survival. Prolonged survival of B cells is a known predisposing factor to the development of autoimmunity and B lymphoma.
9,10 Indeed, aging B-TRAF3 À/À mice developed high levels of serum autoantibodies to double-stranded DNA as well as immune-complex glomerulonephritis. 5 Autoimmunity itself is recognized as a risk factor of B lymphoma in patients with systemic lupus erythematosus or Sjogren's syndrome.
11 Hence, B-TRAF3 À/À mice may be predisposed to B-cell malignancies. Here we report that B-TRAF3 À/À mice spontaneously developed clonal splenic MZL or B1a lymphomas by the age of 18 months.
We first noticed that B-TRAF3
À/À mice have markedly decreased survival rate at ages 49 months (Figure 1a) . We examined tissues of 50 B-TRAF3
À/À mice 9 --18 months of age, 18 that were necropsied when moribund and 32 that had no external signs of disease at the time of study. All 18 moribund B-TRAF3
À/À mice and 20 out of the other 32 (62.5%) had splenic B lymphoma (Supplementary Table 1 
